Acrivon Therapeutics to Showcase AP3 Platform and Clinical Program Updates at Upcoming R&D Event
Key Insights
Acrivon Therapeutics will host a virtual R&D event on March 25, 2025, featuring presentations on their Generative Phosphoproteomics AP3 platform and updates on clinical programs ACR-368 and ACR-2316.
The event will include insights from leading gynecologic oncology experts and will highlight Acrivon's proprietary OncoSignature companion diagnostics, which has received FDA Breakthrough Device designations for ovarian and endometrial cancers.
Acrivon's lead candidate ACR-368 (prexasertib) is advancing in a potentially registrational Phase 2 trial with FDA Fast Track designation for platinum-resistant ovarian and endometrial cancers.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) announced plans to host a virtual R&D event on March 25, 2025, from 4:00 p.m. to 5:15 p.m. ET. The clinical-stage precision medicine company will provide updates on its proprietary Acrivon Predictive Precision Proteomics (AP3) platform capabilities and share clinical developments for its lead programs ACR-368 and ACR-2316.
The event will feature presentations from Acrivon's leadership team alongside renowned endometrial cancer (search) key opinion leaders, followed by an interactive Q&A session. Notable participants include Dr. Mansoor Raza Mirza, chief oncologist at Copenhagen University Hospital and vice president of the European Society of Gynecological Oncology; Dr. Robert L. Coleman, co-director of the Gynecologic Oncology Group Partners Foundation; and Dr. Jesper Olsen, professor at the University of Copenhagen and academic co-founder of Acrivon.
AP3 Platform: Advancing Precision Oncology
At the core of Acrivon's approach is its proprietary Generative Phosphoproteomics platform, AP3, which measures compound-specific effects on tumor cell protein signaling networks and drug-induced resistance mechanisms. This technology generates terabytes of high-resolution quantitative data that enables pathway-based drug design, indication finding, and response prediction.
The AP3 platform has facilitated the development of Acrivon's OncoSignature companion diagnostics, designed to identify patients most likely to benefit from specific treatments. This precision medicine approach aims to match patients with therapies based on the molecular characteristics of their tumors, potentially improving treatment outcomes while reducing unnecessary exposure to ineffective therapies.
ACR-368: Targeting CHK1 and CHK2 in Gynecologic Cancers
Acrivon's lead candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting checkpoint kinases CHK1 (search) and CHK2 (search). The drug is currently advancing through a potentially registrational Phase 2 trial across multiple tumor types.
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer (search). This designation may expedite the development and review process for addressing serious conditions with unmet medical needs.
The company's ACR-368 OncoSignature test has been extensively evaluated in preclinical studies, including two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies from past Phase 2 trials in ovarian cancer (search) patients. The FDA has granted Breakthrough Device designations for the ACR-368 OncoSignature assay for identifying patients with endometrial or ovarian cancer who may benefit from ACR-368 treatment, though the test has not yet obtained regulatory approval.
ACR-2316: Novel WEE1/PKMYT1 Inhibitor
The upcoming event will also provide updates on ACR-2316, Acrivon's second clinical-stage asset. This novel, potent, selective WEE1 (search)/PKMYT1 (search) inhibitor is designed for superior single-agent activity through strong activation of CDK1 (search), CDK2 (search), and PLK1 (search) to drive pro-apoptotic cell death.
Preclinical studies have demonstrated ACR-2316's potential advantages over benchmark inhibitors, and the company will likely share early Phase 1 data during the R&D event. This compound represents Acrivon's internally discovered pipeline programs leveraging co-crystallography and the AP3 platform.
Computational Analytics and Future Directions
Acrivon has developed its AP3 Interactome, a proprietary computational analytics platform driven by Generative Phosphoproteomics machine learning. This system enables integrated comprehensive analyses across all large, in-house AP3 phosphoproteomic drug profiling data sets to advance research programs.
Beyond ACR-368 and ACR-2316, the company is also advancing a preclinical cell cycle program with an undisclosed target, further expanding its precision oncology pipeline.
The virtual R&D event will be accessible via webcast through the Events & Presentations page within the investor section of Acrivon's website. The webcast will remain available for at least 30 days following the event, providing stakeholders with extended access to the presented information.